Antiviral Drugs - CIS

According to the projections, the revenue in the Antiviral Drugs market in the CIS is estimated to reach US$331.90m in 2024.
It is expected that the revenue will demonstrate an annual growth rate (CAGR 2024-2029) of 1.33%, leading to a market volume of US$354.50m by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue in the market, amounting to US$30,640.00m in 2024.
The demand for antiviral drugs in the CIS market is increasing due to the region's high prevalence of viral infections.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in CIS has been showing some interesting trends and developments in recent years.

Customer preferences: Customers in CIS are increasingly demanding antiviral drugs that are not only effective but also affordable. They are looking for drugs that can offer them relief from viral infections while not burning a hole in their pockets. This is one of the main reasons why generic antiviral drugs are becoming more popular in the region.

Trends in the market: The Antiviral Drugs market in CIS is witnessing a steady growth due to the increasing number of viral infections in the region. The COVID-19 pandemic has further accelerated this growth, with many pharmaceutical companies investing heavily in the development of antiviral drugs to combat the virus. In addition, the growing awareness about the benefits of antiviral drugs and the increasing availability of generic drugs are also contributing to the growth of the market.

Local special circumstances: CIS is a region that comprises several countries, each with its own unique set of circumstances. For instance, Russia is the largest country in the region and has a well-established pharmaceutical industry. On the other hand, countries like Kazakhstan and Uzbekistan are still developing their pharmaceutical industries and are heavily reliant on imports. These differences in the level of development of the pharmaceutical industry are reflected in the Antiviral Drugs market in CIS.

Underlying macroeconomic factors: The Antiviral Drugs market in CIS is influenced by several macroeconomic factors, including the GDP of the countries in the region, the level of healthcare spending, and the regulatory environment. For instance, countries with higher GDPs and higher levels of healthcare spending tend to have more developed pharmaceutical industries and a larger market for Antiviral Drugs. In addition, the regulatory environment in each country can also impact the growth of the market, with some countries having more stringent regulations than others.In conclusion, the Antiviral Drugs market in CIS is growing steadily, driven by increasing customer demand for affordable and effective drugs, the growing awareness about the benefits of antiviral drugs, and the COVID-19 pandemic. However, the level of development of the pharmaceutical industry and the regulatory environment in each country can impact the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.